PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Mereo BioPharma Grp (MPH)

Mereo BioPharma Grp

Director/PDMR Shareholding
RNS Number : 7965X
Mereo BioPharma Group plc
01 May 2019
 

Mereo BioPharma Group plc

 

 ("Mereo" or the "Company")

 

Notification of Director Dealing

 

London, May 1, 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 29 April 2019, Darcy Nicolle, a person closely associated (PCA) with Wills Hughes-Wilson, Head of Patient Access, purchased 8000 ordinary shares at a price of GBP1.19 per share.

 

On 30 April 2019, Charles Sermon, General Counsel of Mereo BioPharma, purchased 6456 American Depositary Shares (ADSs) at a price of USD6.00 per share and Richard Jones, Chief Financial Officer of Mereo BioPharma, purchased 1050 American Depositary Shares (ADSs) at a price of USD6.04 per share.

 

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows.

 

1

Details of the person discharging managerial responsibilities

a)

Name

Darcy Nicolle

2

Reason for the notification

a)

Position/status

Person closely associated (PCA) with Wills Hughes-Wilson, Head of Patient Access

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Ordinary Shares

 

b)

Nature of the transaction

Purchase 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

GBP1.19

8000

 

 

 

d)

Aggregated information:  volume, Price

Aggregated volume: 8000

Aggregated price: GBP1.194

e)

Date of the transaction

2019-04-29

f)

Place of the transaction

AIMX

 

 

1

Details of the person discharging managerial responsibilities

a)

Name

Charles Sermon

2

Reason for the notification

a)

Position/status

General Counsel

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)

 

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD6.00

6456

 

 

d)

Aggregated information:  volume, Price

Aggregated volume: 6456

Aggregated price: USD6.00

e)

Date of the transaction

2019-04-30

f)

Place of the transaction

XNMS

 

 

1

Details of the person discharging managerial responsibilities

a)

Name

Richard Jones

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

ADS

 

b)

Nature of the transaction

Purchase  

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD5.94

1050

 

 

 

d)

Aggregated information:  volume, Price

Aggregated volume: 1050

Aggregated price: USD5.94

e)

Date of the transaction

2019-04-30

f)

Place of the transaction

XNMS

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHZFLFBKEFZBBE
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close